|
1
|
Ferlay J, Shin HR, Bray F, Forman D,
Mathers C and Parkin DM: Estimates of worldwide burden of cancer in
2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chen W, Zheng R, Zhang S, Zeng H, Xia C,
Zuo T, Yang Z, Zou X and He J: Cancer incidence and mortality in
China, 2013. Cancer Lett. 401:63–71. 2010. View Article : Google Scholar
|
|
3
|
Arnold M, Soerjomataram I, Ferlay J and
Forman D: Global incidence of oesophageal cancer by histological
subtype in 2012. Gut. 64:381–387. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Tefferi A and Vardiman JW: Myelodysplastic
syndromes. N Engl J Med. 361:1872–1885. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
da Silva-Coelho P, Kroeze LI, Yoshida K,
Koorenhof-Scheele TN, Knops R, van de Locht LT, de Graaf AO, Massop
M, Sandmann S, Dugas M, et al: Clonal evolution in myelodysplastic
syndromes. Nat Commun. 8:150992017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Montalban-Bravo G and Garcia-Manero G:
Myelodysplastic syndromes: 2018 update on diagnosis,
risk-stratification and management. Am J Hematol. 93:129–147. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Demandante CG, Troyer DA and Miles TP:
Multiple primary malignant neoplasms: Case report and a
comprehensive review of the literature. Am J Clin Oncol. 26:79–83.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Rice TW, Ishwaran H, Ferguson MK,
Blackstone EH and Goldstraw P: Cancer of the esophagus and
esophagogastric junction: An eighth edition staging primer. J
Thorac Oncol. 12:36–42. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Arber DA, Orazi A, Hasserjian R, Thiele J,
Borowitz MJ, Le Beau MM, Bloomfield CD, Cazzola M and Vardiman JW:
The 2016 revision to the World Health Organization classification
of myeloid neoplasms and acute leukemia. Blood. 127:2391–2405.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Liu L, Liu X, Sun Y, Zeng Y, Tang X, Li X,
Liu J, Xiao R, et al: Esophageal squamous cell cancer coincidence
with myelodysplastic syndrome/acute myelogenous leukemia. Figshare.
simpledoi.org/10.6084/m9.figshare.12349877.v1May
21–2020
|
|
11
|
Abnet CC, Arnold M and Wei WQ:
Epidemiology of esophageal squamous cell carcinoma.
Gastroenterology. 154:360–373. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Song Y, Li L, Ou Y, Gao Z, Li E, Li X,
Zhang W, Wang J, Xu L, Zhou Y, et al: Identification of genomic
alterations in oesophageal squamous cell cancer. Nature. 509:91–95.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Adès L, Itzykson R and Fenaux P:
Myelodysplastic syndromes. Lancet. 383:2239–2252. 2018. View Article : Google Scholar
|
|
14
|
Poynter JN, Richardson M, Roesler M, Blair
CK, Hirsch B, Nguyen P, Cioc A, Cerhan JR and Warlick E: Chemical
exposures and risk of acute myeloid leukemia and myelodysplastic
syndromes in a population-based study. Int J Cancer. 140:23–33.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Du Y, Fryzek J, Sekeres MA and Taioli E:
Smoking and alcohol intake as risk factors for myelodysplastic
syndromes (MDS). Leuk Res. 34:1–5. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Li QL, Ma JA, Li HP, Huang RB, Hu CH, Liu
XL, Gao YW, Feng GH and Wu F: Synchronous colorectal cancer and
multiple myeloma with chest wall involvement: Is this a
coincidence? Curr Probl Cancer. 41:413–418. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hara M and Hoshijima T: Philadelphia
chromosome (Ph1) positive acute myelomonocytic leukemia with
esophageal cancer: A case report. Rinsho Ketsueki. 33:964–968.
1992.(In Japanese). PubMed/NCBI
|
|
18
|
Stölzel F, Mohr B, Kramer M, Oelschlagel
U, Bochtler T, Berdel WE, Kaufmann M, Baldus CD, Schafer-Eckart K,
Stuhlmann R, et al: Karyotype complexity and prognosis in acute
myeloid leukemia. Blood Cancer J. 6:e3862016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Han L, Madan V, Mayakonda A, Dakle P, Woon
TW, Shyamsunder P, Nordin HBM, Cao Z, Sundaresan J, Lei I, et al:
Chromatin remodeling mediated by ARID1A is indispensable for normal
hematopoiesis in mice. Leukemia. 33:2291–2305. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Eisfeld AK, Kohlschmidt J, Mrozek K, Mims
A, Walker CJ, Blachly JS, Nicolet D, Orwick S, Maharry SE, Carroll
AJ, et al: NF1 mutations are recurrent in adult acute myeloid
leukemia and confer poor outcome. Leukemia. 32:2536–2545. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hu N, Kadota M, Liu H, Abnet CC, Su H, Wu
H, Freedman ND, Yang HH, Wang C, Yan C, et al: Genomic landscape of
somatic alterations in esophageal squamous cell carcinoma and
gastric cancer. Cancer Res. 76:1714–1723. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Golub TR, Barker GF, Lovett M and
Gilliland DG: Fusion of PDGF receptor beta to a novel ets-like
gene, tel, in chronic myelomonocytic leukemia with t(5;12)
chromosomal translocation. Cell. 22:307–316. 1994. View Article : Google Scholar
|
|
23
|
Heilmann AM, Schrock AB, He J, Nahas M,
Curran K, Shukla N, Cramer S, Draper L, Verma A, Erlich R, et al:
Novel PDGFRB fusions in childhood B- and T-acute lymphoblastic
leukemia. Leukemia. 31:1989–1992. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Shimomura Y, Maruoka H and Ishikawa T:
Marked response to imatinib mesylate in a patient with
platelet-derived growth factor receptor beta-associated acute
myeloid leukemia. Int J Hematol. 105:697–701. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Yoshida K, Kuniyasu H, Yasui W, Kitadai Y,
Toge T and Tahara E: Expression of growth factors and their
receptors in human esophageal carcinomas: Regulation of expression
by epidermal growth factor and transforming growth factor alpha. J
Cancer Res Clin Oncol. 119:401–407. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Uguen A and De Braekeleer M: ROS1 fusions
in cancer: A review. Future Oncol. 12:1911–1928. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Rimkunas VM, Crosby KE, Li D, Hu Y, Kelly
ME, Gu TL, Mack JS, Silver MR, Zhou X and Haack H: Analysis of
receptor tyrosine kinase ROS1-positive tumors in non-small cell
lung cancer: Identification of a FIG-ROS1 fusion. Clin Cancer Res.
18:4449–4457. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Roskoski R Jr: ROS1 protein-tyrosine
kinase inhibitors in the treatment of ROS1 fusion protein-driven
non-small cell lung cancers. Pharmacol Res. 121:202–212. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Drilon A, Ou SI, Cho BC, Kim DW, Lee J,
Lin JJ, Zhu VW, Ahn MJ, Camidge DR, Nguyen J, et al: Repotrectinib
(TPX-0005) is a next-generation ROS1/TRK/ALK inhibitor that
potently inhibits ROS1/TRK/ALK solvent-front mutations. Cancer
Discov. 8:1227–1236. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Isobe M, Emanuel BS, Givol D, Oren M and
Croce CM: Localization of gene for human p53 tumour antigen to band
17p13. Nature. 320:84–85. 1986. View
Article : Google Scholar : PubMed/NCBI
|
|
31
|
Preudhomme C and Fenaux P: The clinical
significance of mutations of the P53 tumour suppressor gene in
haematological malignancies. Br J Haematol. 98:502–511. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Nabinger SC, Chen S, Gao R, Yao C,
Kobayashi M, Vemula S, Fahey AC, Wang C, Daniels C, Boswell HS, et
al: Mutant p53 enhances leukemia-initiating cell self-renewal to
promote leukemia development. Leukemia. 33:1535–1539. 2019.
View Article : Google Scholar : PubMed/NCBI
|
